Key terms
About RVMD
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RVMD news
Today
7:30am ET
Analysts Are Bullish on Top Healthcare Stocks: Intuitive Surgical (ISRG), Revolution Medicines (RVMD)
Apr 12
7:49am ET
Revolution Medicines price target raised to $45 from $43 at Oppenheimer
Apr 12
7:47am ET
Oppenheimer Sticks to Their Buy Rating for Revolution Medicines (RVMD)
Apr 12
6:50am ET
Revolution Medicines price target raised to $46 from $36 at Needham
Apr 12
6:26am ET
Buy Rating Justified by Revolution Medicines’ Promising Preclinical Data in KRAS Mutant Cancer Therapies
Apr 12
6:26am ET
Revolution Medicines Receives Buy Rating Amid Promising Cancer Treatment Data and Expanded Market Opportunities
Apr 08
11:40am ET
Revolution Medicines announces publications on discovery of RMC-7977
Apr 08
6:35am ET
Revolution Medicines’ Robust Cancer Drug Pipeline Justifies Buy Rating
Apr 08
6:16am ET
Revolution Medicines’ RMC-9805 Outperforms with High ORR and Promising Clinical Potential
Mar 11
9:57am ET
Disney initiated, Foot Locker upgraded: Wall Street’s top analyst calls
Mar 11
5:05am ET
Buy Rating on Revolution Medicines Amid Promising RMC-6236 Trials for Multiple Cancer Treatments
Mar 11
4:55am ET
Revolution Medicines initiated with an Overweight at Piper Sandler
Mar 08
6:26am ET
Revolution Medicines: A Strong Buy on Promising Drug Prospects and Financial Stability
Mar 08
6:14am ET
Revolution Medicines price target raised to $44 from $28 at H.C. Wainwright
Mar 07
7:15am ET
Revolution Medicines (RVMD) Receives a Buy from TD Cowen
Mar 04
5:28pm ET
Revolution Medicines files automatic mixed securities shelf
Feb 27
11:36pm ET
Buy Rating Affirmed for Revolution Medicines: Advancing RAS Inhibitors and Strong Financial Outlook
Feb 27
8:30am ET
Analysts Are Bullish on Top Healthcare Stocks: Celldex (CLDX), Revolution Medicines (RVMD)
Feb 27
8:17am ET
Revolution Medicines price target raised to $42 from $41 at Wedbush
Feb 27
5:58am ET
Buy Rating Affirmed on Revolution Medicines: Anticipated Oncology Breakthroughs in H2 2024
Feb 26
10:35pm ET
TD Cowen Sticks to Their Buy Rating for Revolution Medicines (RVMD)
Feb 26
4:17pm ET
Revolution Medicines sees FY24 GAAP net loss $480M-$520M
Feb 26
4:16pm ET
Revolution Medicines reports Q4 EPS ($1.14) , consensus (88c)
No recent press releases are available for RVMD
RVMD Financials
Key terms
Ad Feedback
RVMD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RVMD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
